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Abstract
Fatty acid synthesis and oxidation are frequently exacerbated in leukemia cells,
and may therefore represent a target for therapeutic intervention. In this work we
analyzed the apoptotic and chemo-sensitizing action of the fatty acid oxidation
inhibitor etomoxir in human acute myeloid leukemia cells. Etomoxir caused
negligible lethality at concentrations up to 100 mM, but efficaciously cooperated to
cause apoptosis with the anti-leukemic agent arsenic trioxide (ATO, Trisenox), and
with lower efficacy with other anti-tumour drugs (etoposide, cisplatin), in HL60 cells.
Etomoxir-ATO cooperation was also observed in NB4 human acute promyelocytic
cells, but not in normal (non-tumour) mitogen-stimulated human peripheral blood
lymphocytes. Biochemical determinations in HL60 cells indicated that etomoxir
(25–200 mM) dose-dependently inhibited mitochondrial respiration while slightly
stimulating glycolysis, and only caused marginal alterations in total ATP content
and adenine nucleotide pool distribution. In addition, etomoxir caused oxidative
stress (increase in intracellular reactive oxygen species accumulation, decrease in
reduced glutathione content), as well as pro-apoptotic LKB-1/AMPK pathway
activation, all of which may in part explain the chemo-sensitizing capacity of the
drug. Etomoxir also cooperated with glycolytic inhibitors (2-deoxy-D-glucose,
lonidamine) to induce apoptosis in HL60 cells, but not in NB4 cells. The combined
etomoxir plus 2-deoxy-D-glucose treatment did not increase oxidative stress,
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caused moderate decrease in net ATP content, increased the AMP/ATP ratio with
concomitant drop in energy charge, and caused defensive Akt and ERK kinase
activation. Apoptosis generation by etomoxir plus 2-deoxy-D-glucose was further
increased by co-incubation with ATO, which is apparently explained by the capacity
of ATO to attenuate Akt and ERK activation. In summary, co-treatment with
etomoxir may represent an interesting strategy to increase the apoptotic efficacy of
ATO and (with some limitations) 2-deoxy-D-glucose which, although clinically
important anti-tumour agents, exhibit low efficacy in monotherapy.
Introduction
The acquisition of the tumor phenotype involves a profound re-organization of
cellular metabolism, in such a manner that the altered metabolic pathways may
represent potential targets for therapeutic intervention [1–3]. The best known
example is the switch from oxidative phosphorylation to glycolysis as the main
source of energy, even under aerobic conditions (aerobic glycolysis, or ‘‘Warburg
effect’’). No matter of the mechanisms responsible for this transformation, this
property prompted the assay of anti-glycolytic agents, such as 2-deoxy-D-glucose
(2-DG), lonidamine and 3-bromopyruvate (3-BrP), as potential anticancer agents,
and promissory results have been obtained in clinical trials [4–6]. In addition to
glycolytic addiction, tumour cells exhibit increased rates of fatty acid synthesis and
glutamine utilization, which may also represent important therapeutic targets. In
fact, fatty acid and glutamine metabolism provide necessary constituents to
sustain rapid cell growth, and what is also important they may provide cancer cells
with an alternative source of energy [2, 3, 7].
Etomoxir is an oxirane carboxylic acid derivative which irreversible inhibits
carnitine palmitoyl transferase 1 (CPT1) activity [8], thus impeding fatty acid
transport into mitochondria and further catabolism by b-oxidation. As a
compensatory mechanism, inhibition of fatty acid oxidation may promote the
energetically more efficient glucose oxidation. Because of this, etomoxir has been
clinically used as a hypoglycemic drug against diabetes mellitus, and also to
improve energy efficiency in chronic heart failure [9, 10]. In addition, later reports
indicated that etomoxir triggers apoptosis, and what is probably more important,
at low (sub-lethal) concentrations sensitizes to apoptosis induction by some
conventional anti-tumour drugs [11–13], suggesting that it may represent a
valuable tool in anticancer therapies. Nonetheless, this response is not universal
[14], and what is more the mechanisms accounting for the pro-apoptotic action
of etomoxir are not well understood. It has been proposed that fatty acid
oxidation inhibition causes direct perturbations in Bcl-2 family proteins, which
may explain potentiation of apoptosis by the Bcl-2 antagonist ABT-737 and
perhaps other mitochondria-targeting drugs [12]. Other studies indicated that
etomoxir causes ATP depletion as well as oxidative stress (increased reactive
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oxygen species (ROS) production and/or reduced glutathione (GSH) depletion),
which are important determinants of cell death. However these responses were
generally documented at high (lethal) drug concentrations [15–17], but not at low
(sensitizing-inducing) concentrations [12]. Finally, the capacity of etomoxir to
affect protein kinase pathways, important for apoptosis signaling, is almost
unexplored.
Arsenic trioxide (ATO, Trisenox) is a clinically established drug for the
treatment of acute promyelocytic leukemia (APL) [18]. At low concentrations
(0.25–1.0 mM in plasma) the drug blocks cell growth and promotes terminal
differentiation by disrupting the promyelocytic leukemia-retinoic acid receptor
alpha (PML-RARa) oncogenic fusion protein, characteristic of APL. In addition,
at higher concentrations ATO causes apoptosis in this and other cell types, a
property which offers the possibility of extending the therapeutic application of
the drug, especially against haematological malignancies [19, 20]. Nonetheless this
latter approach would require the use of sensitizing strategies, to increase drug
efficacy and reduce dosage to clinically achievable concentrations. As a part of a
research program on the effects of metabolic inhibitors, we recently demonstrated
the efficacy of the glycolytic inhibitors 2-DG, lonidamine and 3-BrP to cause
apoptosis and/or augment the apoptotic efficacy of ATO and other anti-tumour
drugs in leukemia cell models, but the results were discrepant in terms of drug
potency, sensitization pattern, and death regulatory mechanisms [21–23]. In the
present work we investigate the sensitizing capacity of etomoxir in HL60 cells, a
human acute myeloid leukemia (AML) cell line characterized as poorly sensitive
to ATO [24], and analyze the potential importance of alterations in energy
pathways, oxidative stress and specific protein kinase activities as regulatory
mechanisms. The obtained results demonstrate that etomoxir greatly potentiates
ATO lethality, a response further improved by combination with glycolytic
inhibitors. Generation of moderate oxidative stress and activation of the liver
kinase B1/AMP-activated kinase (LKB-1/AMPK) pathway may in part explain the
sensitizing capacity of etomoxir.
Materials and Methods
Reagents and antibodies
All components for cell culture were obtained from Invitrogen, Inc. (Carlsbad,
CA). 4,6-diamino-2-phenylindole (DAPI) was obtained from Serva (Heidelberg,
Germany), and dichlorodihydrofluorescein diacetate (H2DCFDA) and mono-
chlorobimane from Molecular Probes, Inc. (Eugene, OR). The kinase inhibitors 6-
[4(2-Piperidin-1-yl-ethoxy)phenyl)]-3-pyridin-4-yl-pyyrazolo[1,5-a] pyrimidine
(Compound C), 1,4-Diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene
(U0126), 29-amino-39-methoxyflavone (PD 98059), 2-(4-Morpholinyl)-8-phenyl-
4H-1-benzopyran-4-one (LY 294002), 5-Dihydro-5-methyl-1-b-D-ribofuranosyl-
1,4,5,6,8-pentaazaacenaphtylen-3-amine hydrate (triciribine hydrate, Akt inhibi-
tor V, AktiV), and the caspase inhibitor Z-Val-Ala-Asp(OMe)-CH2F (z-VAD-
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fmk), were obtained from Calbiochem (Darmstad, Germany). Rabbit anti-human
AMPKa, p44/42 MAP kinase, phospho-p44/p42 MAPK (Thr202/Tyr204), Akt,
phospho-Akt (Ser473) (D9E) XP, and caspase-3 polyclonal antibodies; and rabbit
anti-human phospho-AMPKa (Thr172) (40H9) and phospho-LKB1 (Ser428)
(C6743) monoclonal antibodies, were obtained from Cell Signaling Technology
Inc (Danvers, MA). Peroxidase-conjugated immunoglobulin G antibodies were
from DAKO Diagnostics, S.A. (Barcelona, Spain). All other non-mentioned
reagents and antibodies were from Sigma (Madrid, Spain).
Cells and treatments
HL60 human myeloblastic leukemia cells [25] were obtained from our
institutional repository (CIB), and PML-RARa-expressing NB4 human promye-
locytic leukemia cells [26] were kindly provided by Profs. J. Leo´n and M.D.
Delgado (Departamento de Biologı´a Molecular, Facultad de Medicina,
Universidad de Cantabria, Santander, Spain). Authentication by STR analysis,
specific antigen expression and other functional markers, as well as the absence of
mycoplasma contamination, was corroborated by us or our technical staff.
Human peripheral blood lymphocytes (PBLs) from healthy voluntary donors were
obtained from buffy-coats supplied by the blood bank of the ‘‘Centro de
Transfusion de la Comunidad de Madrid’’. The samples were provided without
any information about the donor, ant tested to ensure the absence of pathogens.
The whole procedure, including the use of leukemia cell lines and PBLs, was
approved by the Bioethics and Biosafety Commission of our Institution (Centro
de Investigaciones Biolo´gicas, CSIC). Conditions of cell growth and treatment,
including PBLs preparation and mitogenic stimulation with phytohemagglutinin/
interleukin-2, were already described in detail in preceding publications [21, 22].
Stock solutions of orlistat (40 mM), lonidamine (100 mM), etoposide (20 mM)
H2DCFDA (5 mM), Compound C, U0126, PD 98059, LY 294002 and AktiV
(20 mM each), z-VAD-fmk (25 mM), oligomycin (1 mM) and monochlorobi-
mane (200 mM), were prepared in dimethyl sulfoxide. 3(4,5-Dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) was dissolved at 5 mg/ml
in PBS, and oligomycin in RPMI 1640 at 31.6 mM. Stock solutions of etomoxir
(10 mM) and cis-platinum(II)-diammine dichloride (cisplatin, CDDP, 3.3 mM)
were prepared in distilled water. All these solutions were stored at 220 C˚. Stock
solutions of DAPI (10 mg/ml) and propidium iodide (PI, 1 mg/ml) were prepared
in phosphate buffered saline (PBS). ATO was initially dissolved in a small amount
of 1 N NaOH, and then diluted with PBS to give a final concentration of 10 mM.
These solutions were stored at 4 C˚. 2-DG was freshly prepared at 250 mM in PBS.
3-BrP was freshly prepared at 30 mM in PBS, and the pH of the solution was
adjusted at 7.2 with NaOH.
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Flow cytometry
The analysis of samples was carried out on an EPICS XL flow cytometer (Coulter,
Hialeah, FL) equipped with an air-cooled argon laser tuned to 488 nm. The
specific fluorescence signal corresponding to fluorescein isothiocyanate and
H2DCFDA was collected with a 525-nm band pass filter, and the signal
corresponding to PI with a 620-nm band pass filter. A total of 104 cells were
scored in cell cycle assays, and 56103 cells in the H2DCFDA assays.
Cell viability, cell cycle, apoptosis and necrosis
Cell viability was normally determined by the MTT colorimetric assay. This
procedure gives an indirect estimation of the relative number of viable cells in the
culture, based on changes in mitochondrial metabolic activity. However in the
case of etoposide and cisplatin, which cause cell hypertrophy with increased
amount of mitochondria per cell, proliferation was measured by direct cell
counting. Cell cycle phase distribution was routinely determined by cell
permeabilization followed by PI staining and flow cytometry analysis, and the
histograms analyzed with the Cyflogic analysis program (CyFlo Ltd., Turku,
Finland). This technique also provided an estimation of the frequency of
apoptotic cells, characterized by low (sub-G1) DNA content. In all experiments,
apoptosis was also evaluated as the fraction of cells with condensed/fragmented
chromatin, and occasionally chromatin loss, as determined by cell permeabiliza-
tion followed by DAPI staining and microscopy examination. The criterion used
for necrosis (either genuine, ‘‘primary’’ necrosis or apoptosis-derived, ‘‘second-
ary’’ necrosis) was the loss of plasma membrane integrity, as determined by free PI
uptake into non-permeabilized cells and flow cytometry analysis. A detailed
description of all these techniques can be found in our preceding works ([27, 28]
and references therein), and hence is omitted here.
Oxygen consumption and rate of extracellular acidification
The oxygen consumption rate (OCR) and the extracellular acidification rate
(ECAR, a proxy for lactate production) were simultaneously determined using an
XF24 Seahorse Bioscience instrument (North Billerica, MA) (Wu et al., 2007). The
adaptation of the procedure to HL60 cells was described in detail in our preceding
work [23].
ATP, ADP and AMP levels
The total intracellular ATP content was quantified using the ATP
Bioluminescence Assay Kit ASII (Roche, Mannheim, Germany), which measures
ATP based on a luciferase-catalized luciferin oxidation reaction. Samples of
approximately 106 cells were washed once with PBS and then processed according
to the manufacturer’s protocol. The ATP-derived fluorescent signal was measured
on a Varioskan Flash microplate reader (Thermo Fisher Scientific Inc, Waltham,
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MA). Cell samples were collected in parallel to take into account possible
variations in protein content, and the ATP values were normalized accordingly.
The relative adenine nucleotide (AMP, ADP and ATP) pools were determined
by reverse-phase high performance liquid chromatography (HPLC) essentially as
described by De Korte et al. [29]. 46106 cells were spun for 30 seconds at
16,0006g, the supernatant removed and the pellet rapidly quenched and re-
suspended in 660 mM HClO4 and 10 mM theophylline. Extracts were centrifuged
15 min at 16,0006g and the supernatants neutralized using 2.8 M K3PO4.
Analytical separation was performed using a Shimadzu Prominence chromato-
graph (Canby, OR) equipped with a C18 column (Mediterranea SEA 18,
Teknokroma, Sant Cugat, Spain). Peak identities were confirmed by comparison
with the retention times of standard adenine nucleotides, and extracts from cells
exposed to 1 mM oligomycin plus 30 mM 2-DG were used to validate the
technique (S1 Figure).
ROS and GSH levels
The intracellular accumulation of ROS was measured by flow cytometry using the
ROS-sensitive probe H2DCFDA. The intracellular GSH content was determined
in a Varioskan Flash microplate reader at excitation wavelength of 390 nm and
emission wavelength of 520 nm, using the fluorescent probe monochlorobimane.
The detailed protocols were already described in a previous publication [23].
Immunoblotting
Cells were collected by centrifugation, washed with PBS and total protein extracts
were obtained by lysing them for 20 min at 4 C˚ in a buffer consisting of 20 mM
Tris-HCl (pH 7.5) containing 137 mM NaCl, 2 mM EDTA, 10% (v/v) glycerol,
and 1% Nonidet P-40, and supplemented with a protease inhibitor cocktail,
1 mM sodium orthovanadate, and 10 mM NaF. After brief sonication and
centrifugation for 15 min at 10,0006g at 4 C˚, the supernatants were collected,
and samples containing equal amounts of proteins were resolved by SDS-
polyacrylamide gel electrophoresis. The proteins were then transferred to
polyvinylidene fluoride (PVDF) membranes and immunodetected, as previously
described [30]. When convenient, the relative band intensities were quantified
using the Quantity One 1-D Analysis Software, version 4.6 (Bio-Rad Laboratories,
Inc, Hercules, CA).
Data analysis and presentation
Except when indicated, all experiments were repeated at least three times, and as a
rule the results are expressed as the mean value ¡ SD. Statistical analyses were
carried out using one way ANOVA with Dunnet or Bonferroni post-test, using the
GraphPad Prism (version 5.00) software (GraphPad software, Inc, LaJolla CA).
The symbols used were: *, to compare treatment vs. control, or pairs of
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treatments; and #, to indicate that the value in a combined treatment is higher
than the sum of values in the corresponding single treatments. In all cases, single
symbol means p,0.05, double symbol p,0.01, and triple symbol p,0.001. n.s.,
non-significant. In some cases, drug interaction was also examined by calculating
the combination index (CI), using the Compusyn software (Combosyn, Inc,
Paramus, NJ), based on the Chou and Talalay procedure [31]. CI values below 1.0
indicate synergism, values around 1.0 additive effect, and values above 1.0
antagonism.
Results
Cell viability, cell cycle and apoptosis
We firstly examined the capacity of etomoxir, alone and in combination with the
anti-leukemic agent ATO, to affect viability and cycle phase distribution, and to
cause apoptosis in HL60 cells. Etomoxir was assayed at concentrations of 50–
200 mM, on the ground of earlier studies in leukemia and myeloma cells [12, 14].
ATO was assayed at 0.5–2 mM, which are considered clinically relevant
concentrations [32]. Cell viability was determined by the MTT assay, and cell cycle
alterations by PI staining and flow cytometry. Apoptosis was estimated as the
frequency of cells with sub-G1 DNA content in the flow cytometry assays, and the
results were always qualitatively corroborated by examining chromatin con-
densation/fragmentation. The results, some of which are represented in Fig. 1,
may be summarized as follows: (i) Incubation with 50–200 mM etomoxir caused
dose-dependent decrease in the number of viable cells (Fig. 1A). At 50–100 mM
the drug caused cell cycle perturbation, consisting in accumulation of cells at S-
phase (Fig. 1B, E), but apoptosis induction was very low (less than 10%) (Fig. 1B,
C). The drug moderately induced apoptosis at 200 mM (30–35% apoptotic cells)
(Fig. 1C, E). (ii) Incubation for 24 h with 0.5–2 mM ATO caused concentration-
dependent decrease in cell viability (Fig. 1A), but little (less than 10%) apoptotic
effect (Fig. 1B, C). (iii) Co-incubation with etomoxir augmented ATO-provoked
viability decrease (Fig. 1A), and also potentiated apoptosis generation reaching
approximately 30–35% apoptotic cells with 100 mM etomoxir and 2 mM ATO
(Figs. 1C, E and S2B Figure). Drug cooperation was initially estimated as more
than additive (Fig. 1C), and synergism could be demonstrated by CI calculation
(CI values of 0.54 and 0.35, using 100 mM etomoxir plus 1 and 2 mM ATO,
respectively). Time-course determinations with 100 mM etomoxir plus 2 mM ATO
indicated 5.1¡1.1%, 8.2¡1.9%, and 15.3¡3.7% apoptotic cells at 4, 8 and 16 h,
respectively, and on this ground 8 h was the maximum treatment time selected for
further studies of regulatory mechanisms. (iv) Etomoxir plus ATO caused
caspase-3 cleavage/activation (Fig. 1D), and the lethality of 200 mM etomoxir
alone or 100 mM etomoxir plus 2 mM ATO was decreased by the pan-caspase
inhibitor z-VAD-fmk (Fig. 1C), indicating bona fide caspase-dependent apopto-
sis. (v) In addition to the expression of apoptotic markers, etomoxir plus ATO
caused plasma membrane damage in a small fraction of cells, as evidenced by free
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PI penetration, but this fraction was almost suppressed by co-treatment with z-
VAD-fmk (11.9¡3.2% vs. 2.3¡1.2% in the absence and presence of the caspase
inhibitor, respectively, at 24 h of treatment with 100 mM etomoxir plus 2 mM
ATO). Hence, plasma membrane permeability likely represents late apoptosis
instead of genuine necrotic response.
Fig. 1. Effect of etomoxir and ATO on cell viability, cycle phase distribution and apoptosis generation in HL60 cells. Cells were incubated for 24 h
with the indicated concentrations of etomoxir (Eto) and ATO, alone and in combination. When nothing is indicated, ATO was used at 2 mM. For convenience,
the drug concentrations are sometimes indicated as subheadings. When indicated, the cells were co-incubated with the pan-caspase inhibitor z-VAD-fmk
(50 mM). (A) Changes in cell viability, as evidenced by the MTTassay. Absorption values are indicated in relation to untreated (Cont) cultures. (B) Frequency
of cells at the different phases of the growth cycle, namely G1, S and G2/M, and with sub-G1 DNA content (apoptotic). Examples of flow cytometry
histograms are presented in (E). (C) Frequency of apoptotic cells, as determined by flow cytometry. (D) Caspase-3 cleavage/activation, determined by
immunoblot. b-actin is included as a loading control. The bar charts in (A–C) represent the mean¡ S.D. of at least three determinations. Symbols mean: (*)
significant differences between the indicated pair values; (#) significant differences between the combined treatment and the sum of values in the
corresponding individual treatments (e.g., co-incubation with 100 mM Eto and 2 mM ATO, in relation to the sum of 100 mM Eto alone plus 2 mM ATO alone)
(n.s., non-significant). To better discern differences, in this case the sum of values in individual treatments is indicated by a horizontal white line within the bar
corresponding to the combined treatment. Single symbol, p,0.05; double symbol, p,0.01; triple symbol, p,0.001.
doi:10.1371/journal.pone.0115250.g001
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In addition, we examined the potential cooperation between etomoxir and
ATO in other cell models, namely NB4 APL cells and mitogen-stimulated
non-tumour PBLs, as well as the potential cooperation between etomoxir and
antitumour drugs other than ATO, namely the DNA topoisomerase II poison
etoposide and the DNA alkylating agent cisplatin, in HL60 cells. The results were
as follows: (i) NB4 cells were similarly sensitive to apoptosis induction by
etomoxir as HL60 cells, but more sensitive to apoptosis induction by ATO
(approximate apoptotic rate of 20% at 24 h incubation with 2 mM), as earlier
described [24]. Etomoxir and ATO cooperated in more than additive manner to
cause apoptosis in NB4 cells, but only at the higher ATO concentration (Fig. 2A).
PBLs were resistant to etomoxir and slightly sensitive to ATO, and the
combination produced null cooperative effect (Fig. 2B) (ii) Etoposide and
cisplatin decreased cell proliferation in HL60 cells (Fig. 2C), concomitantly with
cycle arrest at G2/M (etoposide) or S plus G2/M (cisplatin) (Fig. 2E), and caused
cell hypertrophy (not shown). Co-incubation with etomoxir did not augment
proliferation inhibition (Fig. 2C), although it increased slightly apoptosis
induction by etoposide (0.5 and 1 mM) and cisplatin (2 and 5 mM) (Fig. 2D).
Nonetheless, this increase was of lower magnitude (approximately additive) than
in the case of etomoxir plus ATO. Of note, the lower apoptotic efficacy was not
explained by a switch to a necrotic response, since the frequency of PI permeable
cells always remained below 10% within the 24 h treatment period (data not
shown).
Energy metabolism and oxidative stress
It was reported that etomoxir readily inhibits mitochondrial respiration [12, 17],
and at elevated concentrations causes ATP depletion [15–17]. ATP depletion may
be a determinant for cell death, either apoptosis or necrosis, depending on the
magnitude of the decrease [33, 34]. For these reasons, experiments were carried
out to simultaneously measure OCR and ECAR (a proxy for lactate formation) as
an estimate of the rates of mitochondrial respiration and glycolysis, respectively,
as well as the net ATP content and the relative distribution of adenine nucleotides
in HL60 cells. It was found that 25–200 mM etomoxir dose-dependently inhibited
mitochondrial respiration activity (Fig. 3A), with a concomitant slight increase in
lactate formation (at the concentrations of 50–100 mM) (Fig. 3B). Determinations
of net ATP content by bioluminiscence assay indicated null effects of 25–100 mM
etomoxir, and an approximate 20% decrease at 200 mM, at 4 h of treatment (S3A
Figure). Determinations of adenine nucleotide levels by HPLC showed that 2–6 h
exposure to 50–200 mM etomoxir caused slight, concentration-dependent
reduction in the relative ATP fraction paralleled by slight increases in the relative
ADP and AMP fractions, and consequently in AMP/ATP ratio (Fig. 3C, D, and S1
Table).
It was reported that etomoxir may cause oxidative stress, as indicated by ROS
overproduction and/or GSH depletion [15–17, 35]. In addition, the intracellular
oxidant state is an important determinant of ATO toxicity [36, 37]. For these
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reasons, we analyzed possible alterations in intracellular ROS accumulation and
GSH levels in etomoxir-treated HL60 cells. It was observed that incubation for
3–6 h with 50–200 mM etomoxir dose-dependently induced ROS over-accumu-
lation, as measured by the increase in H2DCFDA-derived fluorescence (Fig. 4A,
Fig. 2. Effect of etomoxir, etoposide and cisplatin on cell proliferation, cycle phase distribution and
apoptosis generation in different cell models. Cells were incubated for 24 h with the indicated
concentrations of etomoxir (Eto), ATO, etoposide (ETP) or cisplatin (CDDP), alone or in combination. When
nothing is indicated, etomoxir was used at 100 mM. (A) Apoptosis generation, measured by flow cytometry, in
NB4 cells. (B) The same, in mitogen-stimulated human PBLs. (C, D) Changes in proliferation activity,
measured by cell counting (C), and apoptosis generation, measured by flow cytometry (D), in HL60 cells.
Changes in proliferation are expressed in relation to untreated (Cont) cultures. (E) Flow cytometry histograms
showing changes in cycle distribution in HL60 cell cultures treated with etoposide and cisplatin. The bar charts
in (A–D) represent the mean¡ S.D. of at least three determinations. Symbols and n.s. indicate significant and
non-significant differences, respectively, between the indicated pairs of values (C), or between the combined
treatment and the sum of values in the corresponding individual treatments (A, B, D). For other conditions see
legend of Fig. 1.
doi:10.1371/journal.pone.0115250.g002
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B). In addition, upon 4 h incubation the drug caused a slight, dose-dependent
decrease in intracellular GSH content (Fig. 4C).
Protein kinase activities
We recently reported that the glycolytic inhibitors 2-DG and lonidamine activated
protein kinase B (Akt) and extracellular-signal regulated kinases (ERK) in AML
cells, representing a defensive response which reduces drug lethality, but they
caused drug-dependent differential effects (either inhibition or activation) on the
of LKB-1/AMPK pathway [21, 22]. Since the action of fatty acid inhibitors on
Fig. 3. Effect of etomoxir on energy metabolism in HL60 cells. (A, B) The basal rates of oxygen
consumption (OCR) and extracellular acidification (ECAR, a proxy for lactate formation) were simultaneously
determined upon 1 h exposure to the indicated concentrations of etomoxir on a Seahorse XF24 metabolic flux
analyzer. Data points represent the mean¡ S.D. of six independent experiments performed in sextuplicate.
The results are expressed in relation to the control (OCR: 287.1¡26.3 pmol O2/min; ECAR: 26.8¡3.2 mpH
units/min). (C, D) The relative fraction of ATP in relation to total nucleotide (ATP+ADP+AMP) content (C), and
the AMP/ATP ratio (D), were determined by HPLC upon 2 h exposure to the indicated concentrations of
etomoxir. Data point represents the mean ¡ S.D. of at least four independent experiments. For more
complete information see S1 Table. Symbols indicate significant differences in relation to drug-untreated cells
(0 mM) (n.s., non-significant). For other conditions see legend of Fig. 1.
doi:10.1371/journal.pone.0115250.g003
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these signaling pathways is little known, we examined the capacity of etomoxir
(100 and 200 mM), alone and with ATO, to modulate the phosphorylation/
activation state of these kinases. A representative blot obtained at 4 h of
incubation is shown in Fig. 5A. It was observed that etomoxir caused marginal
effect on Akt phosphorylation, but produced an appreciable increase in ERK
phosphorylation as well as in LKB-1 and AMPK phosphorylation. Similar results
were obtained at 8 h of incubation (data not shown). 2-DG (10 mM), included as
a control, strongly stimulated Akt and ERK phosphorylation but reduced LKB-1
and AMPK basal phosphorylation, as expected [22].
ERK behaves as a defensive kinase [21], and hence its activation may not
explain apoptosis potentiation by etomoxir. On the other hand, AMPK may either
Fig. 4. Effect of etomoxir on ROS and GSH levels in HL60 cells. (A, B) Intracellular accumulation of ROS,
as determined by flow cytometry using H2DCFDA. The results are expressed as fold increase in relation to
untreated (Cont) cells. Histograms corresponding to untreated cells and cells incubated for 3 h with 100 and
200 mM etomoxir are shown as examples. (C) Intracellular GSH levels, as determined at 4 h of incubation by
monochlorobimane derivatization in luminometric assays. 3-BrP (60 mM) was used as a positive control (see
Ref. 23). The results are expressed in relation to untreated (Cont) cells (approximate GSH content, 8.5 nmol/
106 cells). The values represent the mean ¡ S.D. of at least three determinations. Symbols indicate
significant differences in relation to Cont (n.s., non significant). For other conditions see legend of Fig. 1.
doi:10.1371/journal.pone.0115250.g004
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play pro-apoptotic or survival roles [38, 39]. For this reason, we examined the
effect of the AMPK-specific inhibitor compound C (7 mM) on drug lethality. The
capacity of the inhibitor to effectively prevent kinase activation in HL60 cells was
corroborated in a previous work [22]. As indicated in Fig. 5B and S2E Figure,
compound C attenuated the generation of apoptosis by etomoxir plus ATO and
etomoxir plus cisplatin. This indicates that in the present experimental conditions
Fig. 5. Effect of etomoxir on protein kinase activities, and effect of AMPK inhibitor, in HL60 cells. (A) Relative levels of phosphorylated (P) and total (T)
Akt, ERKs, LKB1 and AMPK upon incubation for 4 h with etomoxir and ATO, alone and in combination. Extracts from cells incubated with 10 mM 2-DG,
used as a positive control (see Ref. 21), were run in a parallel lane within the same gel. The level of b-actin was assessed as a control of sample loading.
The numbers inside the blots indicate the values obtained by quantification of band intensities, once normalized in relation to the corresponding b-actin level,
and expressed in relation to the Control (which received the arbitrary value of one). The blots are representative of one out of four independent experiments,
with qualitatively similar results. (B) Apoptosis generation at 24 h of incubation with etomoxir plus either ATO or cisplatin, alone (2) or in combination (+) with
the AMPK inhibitor compound C (CC, 7 mM). The values are the mean¡ S.D. of four determinations. Symbols indicate significant differences between the
indicated pairs of values (n.s., non-significant). ATO was always used at 2 mM. For other conditions see legend of Fig. 1.
doi:10.1371/journal.pone.0115250.g005
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AMPK activation plays a pro-apoptotic role, and hence may in part explain the
increased lethality of the combinatory treatments.
Combination of etomoxir with glycolysis inhibitors
Glycolysis and mitochondrial oxidative phosphorylation represent alternative
energy supply pathways which may mutually compensate [8, 40]. Since etomoxir
inhibited mitochondrial respiration with occasional activation of lactate
production (see Fig. 3), we asked whether a more efficacious apoptotic response
could be obtained by simultaneously targeting the two pathways. Preliminary
experiments indicated that incubation of HL60 cells with 5–10 mM 2-DG caused
concentration-dependent decrease in viability, which was augmented by co-
incubation etomoxir (Fig. 6A), and caused also cell cycle disruption characterized
by cell accumulation at G2/M, with concomitant reduction in S phase and G1
(Fig. 6B). 2-DG alone caused little (lower than 10%) apoptosis at concentrations
below 20 mM, but efficaciously cooperated with etomoxir to induce apoptosis in
more than additive, synergistic manner (Fig. 6C and S2C Figure) (CI values of
0.45 and 0.37, using 100 mM etomoxir and 10 and 20 mM 2-DG, respectively).
Apoptosis was potentiated with similar efficacy using the anti-glycolytic agent
lonidamine instead of 2-DG (Fig. 6D) (CI values of 0.66 and 0.65 using 100 mM
etomoxir and 100 and 150 mM lonidamine, respectively). For comparison,
experiments were carried out using metformin, which inhibited mitochondrial
respiration while enhancing glycolysis in HL60 cells (OCR value of 37% and
ECAR value of 200% in relation to the control, upon 2 h treatment with 4 mM
metformin). Es indicated in Fig. 6E, the benefit of combining etomoxir with
metformin was very low, while treatment with metformin plus 2-DG, used as an
internal control, was highly toxic, as expected [41]. Of note, we could not observe
beneficial cooperation between 2-DG and etomoxir in NB4 cells, a cell line
described as highly dependent on glycolysis [42] and consequently with higher
sensitivity to 2-DG than HL60 cells (e.g., nearly 30% apoptosis upon treatment
with 5 mM 2-DG: Fig. 6G). Concerning mitogen-stimulated PBLs, we could
observe cooperation slightly higher than additive to induce apoptosis between
100 mM etomoxir and 10 mM 2-DG (Fig. 6H), although the intensity of
cooperation was much lower than in the case of HL60 cells (see Fig. 6C). Finally,
we wanted to know whether combining etomoxir with 2-DG could be also
beneficial in terms of cooperation with ATO. In these experiments the
concentration of etomoxir was reduced to 50 mM, to minimize the basal lethality
of etomoxir plus 2-DG combination. It was observed that the rate of apoptosis
obtained with the triple combination (i.e., ATO with etomoxir plus 2-DG) was
clearly higher than that obtained by any double combination (i.e., ATO with
etomoxir, or ATO with 2-DG) in HL60 cells (Fig. 6F and S2D Figure). Similar
results were obtained in the triple combination assay, using lonidamine instead of
2-DG (Fig. 6F).
Looking for possible factors which could explain the increased apoptotic
efficacy and sensitizing capacity of etomoxir plus 2-DG, we examined again
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Fig. 6. Effects of etomoxir in combination with other metabolic inhibitors, in different cell models. (A) Changes in viability, as evidenced by the MTT
assay, in HL60 cells treated with 5 and 10 mM 2-DG, alone and in combination with 100 mM etomoxir. Absorption values are indicated in relation to untreated
(Cont) cultures. (B) Frequency of HL60 cells at the different growth cycle phases and with sub-G1 DNA content (apoptotic) upon incubation with 5–20 mM 2-
DG, alone or with 100 mM etomoxir. (C–E) Frequency of apoptosis in HL60 cell cultures upon incubation with: (C) 100 mM etomoxir and 5–20 mM 2-DG,
alone or in combination; (D) the same, using etomoxir and lonidamine (Lon, 50–150 mM); (E) the same, using etomoxir and metformin (Metf, 4 mM).
Metformin plus 2-DG was included as a positive control. (F) Frequency of apoptosis in HL60 cell cultures incubated with 2 mM ATO in combination with
50 mM etomoxir plus 5 mM 2-DG, in relation to ATO plus 2-DG alone and ATO plus etomoxir alone; and in cultures incubated with 2 mM ATO in combination
with 50 mM etomoxir plus 50 mM lonidamine, in relation to ATO plus lonidamine alone and ATO plus etomoxir alone. (G) Frequency of apoptosis in NBA cell
cultures treated with 1–5 mM 2-DG, alone and in combination with 50–100 mM etomoxir. (H) The same in mitogen-stimulated PBLs, using 10 mM 2-DG and
100 mM etomoxir. All treatments lasted for 24 h. All values are the mean ¡ S.D. of at least four determinations. Symbols in A and F indicate significant
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energy metabolism, oxidative stress, and protein kinase activity modulation in
HL60 cells. The results were as follows: (i) Determinations of net ATP levels by
bioluminescence assay indicated an approximately 50% decrease upon treatment
with 5–10 mM 2-DG alone, which was not significantly augmented by
co-treatment with etomoxir or with etomoxir plus ATO (S3B Figure).
Determination of adenine nucleotide levels revealed that 2-DG caused a slight
decrease in the relative ATP fraction with concomitant increase in the relative
ADP and AMP fractions, and a considerable increase in AMP/ATP ratio with
concomitant drop in energy charge. This response was particularly evident at 6 h
of treatment, and was augmented by co-treatment with etomoxir (etomoxir plus
2-DG), but was not further increased by co-incubation with ATO (ATO plus
etomoxir plus 2-DG) (Fig. 7A, B, and S1 Table). (ii) Concerning oxidative stress,
2-DG did not potentiated ROS production, but instead tended to decrease the
basal ROS content when used alone, and abrogated the increase caused by
etomoxir in the combined treatment. This response was not modified by the
inclusion of ATO (Fig. 7C). In addition, the intracellular GSH content was
minimally affected by etomoxir plus 2-DG, with or without ATO (Fig. 7D). (iv)
Finally, treatment with 2-DG alone greatly stimulated Akt and ERK phosphor-
ylation, and the response was similar (ERK) or even higher (Akt) when combined
with etomoxir (Fig. 8A). Of note, AMPK phosphorylation was attenuated by 2-
DG alone, as expected [22], but kinase phosphorylation was not increased by
etomoxir plus 2-DG, in spite of the increase in AMP/ATP ratio. Importantly, co-
incubation with ATO did not affect AMPK phosphorylation, but attenuated
slightly (Akt) or strongly (ERK) the increase provoked by etomoxir plus 2-DG
(Fig. 8A).
As indicated above, Akt and ERK are normally considered as pro-survival
kinases. Because of this, we wanted to know whether the increase in apoptosis
obtained by addition of ATO could be mimicked by application of standard
kinase inhibitors, namely the phosphatidylinositol 3-kinase (PI3K) inhibitor LY
294002 (30 mM), the Akt inhibitor AktiV (10 mM), and the mitogen-induced
extracellular kinase (MEK)/ERK inhibitors U0126 (2.5 mM) and PD 98059
(30 mM). At these concentrations, the lethality of the inhibitors used alone was
negligible. It was found that co-incubation with kinase inhibitors greatly
stimulated apoptosis generation by etomoxir plus 2-DG (Fig. 8B and S2F Figure).
This corroborates that Akt and ERK play defensive roles, and since ATO is able to
attenuate kinase activation, provides a partial explanation for the higher apoptotic
efficacy of the triple (etomoxir plus 2-DG plus ATO) combination.
differences between the indicated pairs of values. Symbols in C, D, E, G, H, indicate significant differences between the combined treatment and the
corresponding individual treatments (n.s., non-significant). For other conditions see legend of Fig. 1.
doi:10.1371/journal.pone.0115250.g006
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Discussion
The results in this work indicate that the CPT1 inhibitor etomoxir causes
concentration-dependent proliferation inhibition and caspase-dependent apop-
tosis, and sensitizes to apoptosis induction by conventional anti-tumour agents in
HL60 AML cells. The lethality of etomoxir was marginal at concentrations up to
100 mM, but the drug efficaciously cooperated to cause apoptosis with sub-lethal
ATO concentrations. This effect was corroborated in NB4 APL cells, while both
etomoxir lethality and cooperation with ATO were null or negligible in normal
proliferating PBLs, suggesting that the response is somewhat selective for tumour
Fig. 7. Energy metabolism and oxidative stress upon incubation with etomoxir, 2-DG and ATO in HL60
cells. (A, B) Relative fraction of ATP in relation to total nucleotide (ATP+ADP+AMP) content (A), and AMP/
ATP ratio (B), in untreated cells (Cont) and cells incubated for 6 h with the indicated concentrations of 2-DG
and etomoxir, alone and in combination, and in the presence or absence of ATO. For more complete
information see S1 Table. (C, D) Changes in intracellular ROS accumulation (C) and GSH content (D), in cells
incubated for 4 h with etomoxir and 2-DG, alone or in combination, and in the presence or absence of ATO. 3-
BrP (60 mM) was used as a positive control in D (see Ref. 23). The values represent the mean ¡ S.D. of at
least five determinations. Symbols in A–C indicate significant differences in relation to the control or between
the indicated pairs of treatments. Symbols in D indicate significant differences in relation to the control (n.s.,
non-significant). ATO was always used at 2 mM. For other conditions, see legends of Figs. 1 and 4.
doi:10.1371/journal.pone.0115250.g007
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cells. Etomoxir also cooperated with the DNA-targeting agents cisplatin and
etoposide in HL60 cells, a result consistent with earlier observations in other cell
models [11], but the efficacy of this cooperation was clearly lower than in the case
of ATO. Interestingly, Samudio et al. [12] reported that etomoxir potentiated
apoptosis induction by the Bcl-2 antagonist ABT-737 but not by the DNA-
Fig. 8. Effect of 2-DG, etomoxir and ATO on protein kinase activities, and effect of protein kinase
inhibitors, in HL60 cells. (A) Relative levels of phosphorylated (P) and total (T) Akt, ERKs and AMPK, upon
treatment for 4 h with 5 mM 2-DG, alone and in combination with 50 mM etomoxir or etomoxir plus 2 mM ATO.
The level of b-actin was assessed as control of sample loading. The numbers inside the blots indicate the
values obtained by quantification of band intensities, once normalized in relation to the corresponding b-actin
level, and expressed in relation to the Control (arbitrary value of one). The blots are representative of one out
of three independent experiments with qualitatively similar results. (B) Frequency of apoptotic cells upon 24 h
incubation with etomoxir plus 2-DG, and with the PI3K inhibitor LY 294002 (30 mM), the Akt inhibitor triciribine
(AktiV, 10 mM), and the MEK/ERK inhibitors U0126 (5 mM) and PD 98059 (30 mM, alone and in combination
with etomoxir plus 2-DG. The triple ATO plus etomoxir plus 2-DG combination is included for comparison. The
values represent the mean ¡ S.D. of four determinations. Symbols indicate significant differences between
the indicated pairs of values. All other conditions were as in Figs. 1 and 5.
doi:10.1371/journal.pone.0115250.g008
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targeting drug cytarabine in AML cells, and proposed that fatty acid inhibitors
could be particularly efficacious when combined with direct activators of the
intrinsic apoptotic pathway. This is fully consistent with our results, since ATO is
a mitochondriotoxic agent, which directly targets the permeability transition pore
[43]. However other explanations are also possible – e.g., differential sensitivity of
anti-tumour drugs to pro-oxidant environment, as discussed below. We did not
directly examine the effect of etomoxir on fatty acid metabolism in HL60 cells.
Nonetheless, earlier studies indicated that 50–100 mM etomoxir efficaciously
inhibited fatty acid oxidation in other leukemic cell models [14], and we could
observe that ATO toxicity was also potentiated by the fatty acid synthesis inhibitor
orlistat in HL60 cells (S4A, B Figure). While this might indicate that the chemo-
sensitizing action is a consequence of fatty acid oxidation disruption itself, we also
observed discrepant effects on cell cycle progression, namely cell accumulation at
S phase by etomoxir (Fig. 1B) and at G1 by orlistat (S4C, D Figure). Hence, the
possible contribution of drug-specific side effects may not be discarded (see
below).
Looking for possible factors which could explain the pro-apoptotic action of
etomoxir, we firstly examined the capacity to disrupt energy metabolism.
Etomoxir was earlier reported to cause ATP depletion in different cell systems, but
this effect was generally documented at relatively high drug concentrations
(250 mM and above [15–17]). In our experiments treatment of HL60 cells with
25–200 mM etomoxir inhibited mitochondrial respiration, with concomitant
slight increase in lactate formation. This could represent an adaptive mechanism
of the glycolytic machinery to sustain ATP production, and actually the net
intracellular ATP content as well as the relative distribution of nucleotide (ATP,
ADP and AMP) pools was in general little affected. The observed drastic
inhibition of the basal respiration (approximately 65% decrease at 100 mM
etomoxir) deserves an additional comment. Since experiments are performed with
cells incubated in RPMI containing glucose and glutamine, it is striking that
blocking fatty acid oxidation through the inhibition of CPT1 cannot be
substituted, at the mitochondrial level, by pyruvate or glutamine oxidation. This
would suggest that etomoxir could also be inhibiting electron transport at the
respiratory chain. Similar conclusions have been drawn from the analysis of the
respiratory capacity of glioblastoma cells treated with etomoxir [17].
As a second parameter we examined oxidative stress, measured by ROS over-
accumulation and GSH depletion. As in the case of ATP, earlier reports indicated
induction of oxidative stress responses by high concentrations of etomoxir [15–
17], but another study did not detect ROS induction by low drug concentrations
in AML cells [12]. In our experiments 50–200 mM etomoxir caused concentra-
tion-dependent, moderate increase in ROS accumulation, and slight decrease in
intracellular GSH content, in HL60 cells. The augment in ROS would be
surprising if the sole effect of etomoxir is CPT1 inhibition since this would lead to
decreased electron flow in the respiratory chain, and hence decreased ROS
production by mitochondria. However, if etomoxir is also acting on the
respiratory chain, the increased ROS formation would be the expected result of
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the inhibition of electron flow. In addition, it has been reported that saturated
fatty acids such as palmitate stimulate ROS production via activation of
NAD(P)H oxidases, and this effect could be mimicked by etomoxir, which
contains a saturated fatty acid-derived structure [35, 44]. Unfortunately
antioxidants such as N-acetyl-L-cysteine or catalase-polyethylene glycol, satisfac-
torily used in preceding studies [21, 28], were toxic in combination with etomoxir
(data not shown), impeding us to directly prove the functional role of ROS over-
accumulation. Nonetheless, we previously demonstrated that AML cells readily
tolerate moderate ROS increase and/or GSH depletion [23, 45], so that the here
observed fluctuations may not suffice to explain the lethality of etomoxir used
alone. By contrast, moderate oxidative stress may account at least in part for the
potentiation by etomoxir of ATO-provoked apoptosis, since ATO is an oxidative
stress-sensitive drug, the toxicity of which is greatly augmented under conditions
of inherent or experimentally-induced ROS increase [28, 37, 45, 46] or GSH
depletion [23, 24, 36]. Of note, this is not the case of cisplatin and etoposide,
which at low concentrations are little affected by ROS over-production or GSH
depletion in AML cells ([23, 28] and data now shown). Hence, taken together
these results could explain the differential sensitizing capacity of etomoxir when
combined with ATO or with the DNA-targeting drugs.
In addition, we examined the possible role of specific protein kinases on the
pro-apoptotic action of etomoxir. Our preceding studies indicated that 2-DG and
3-BrP rapidly stimulated defensive Akt and ERK phosphorylation/activation, but
down-regulated LKB-1/AMPK phosphorylation in HL60 cells [22, 23]. This
response was apparently surprising, since 2-DG increases the AMP/ATP ratio,
which is a trigger of AMPK activation [38], but was adequately explained by the
antagonism between AMPK and Akt kinases – i.e., Akt activation is a determinant
of AMPK inactivation [22, 23]. In the present experiments etomoxir exerted
negligible effect on Akt phosphorylation, and hence there was not impediment for
LKB-1/AMPK activation. Nonetheless, the mechanism responsible for this
activation is unclear: in fact etomoxir weakly increased the AMP/ATP ratio, but
also stimulated ROS production, and AMPK has been characterized as a ROS-
inducible kinase [45, 47]. This later possibility could not be directly examined, due
to the above indicated toxicity of antioxidant agents. Whatever the case,
experiments with the kinase inhibitor compound C revealed that AMPK
activation positively regulates apoptosis, and hence could in part account for the
potentiation of anti-tumour drug (ATO, cisplatin) lethality in the combined
treatments.
Finally, our results indicate that etomoxir efficaciously cooperates with the
glycolytic inhibitors 2-DG and lonidamine to cause apoptosis in HL60 cells. This
is in agreement with earlier reports using etomoxir plus 2-DG in colon carcinoma
cells [11], and is congruent with the concept that glycolysis and fatty acid
metabolism are potentially compensatory pathways. This is important, since the
clinical efficacy of glycolytic [4, 5] and fatty acid [48] inhibitors in monotherapy is
hampered by their low bio-availability and/or side-toxicities at elevated
concentrations. Nonetheless, the potential application of this combined treatment
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exhibits some limitations. Firstly, the efficacy of cooperation between energy
pathway inhibitors seems to be conditioned by the inherent metabolic properties
of the cancer cell model, as indicated by the poor results obtained with etomoxir
plus 2-DG in the highly ‘‘glycolytic’’ NB4 cell line [42]. In addition, etomoxir plus
2-DG also cooperated to induce apoptosis in mitogen-stimulated non-tumour
PBLs (although with much lower efficacy than in HL60 cells). Finally, the
mechanisms explaining apoptosis potentiation by etomoxir plus 2-DG in HL60
cells are presently unclear. For instance, the combined treatment did not augment
oxidative stress, but instead 2-DG abrogated the etomoxir-stimulated ROS
production, which is in agreement with earlier reports [49, 50]. In addition, the
combined treatment was unable to prevent the activation of defensive Akt and
ERK kinases, in comparison to the effect produced by 2-DG alone. Considering
energy parameters, incubation with etomoxir plus 2-DG caused an approximately
50% decrease in total net ATP content, but this is similar to the decrease produced
by 2-DG alone, and at the lethality of 2-DG at the here-used concentrations (2–
10 mM) is negligible. As the most suggestive result, the combination of etomoxir
plus 2-DG potentiated the relative reduction in energy charge with a concomitant
increase in AMP/ATP ratio, in comparison to either drug alone. Nonetheless, the
functional relevance of this alteration in terms of cell viability remains to be
determined. As a final step, we observed that the apoptotic efficacy of etomoxir
plus 2-DG was further augmented by co-incubation with 2 mM ATO. This may be
also relevant in practical terms, since 2 mM ATO is a clinically attainable
concentration. Again, this response may not be explained by changes in total ATP
content, energy charge, and oxidative stress (ROS production, GSH depletion),
since the effects of etomoxir plus 2-DG were not significantly modified by co-
incubation with ATO. However, the increase in apoptosis may be at least in part
explained by the capacity of ATO to abrogate (ERK) or attenuate (Akt) defensive
Fig. 9. Scheme summarizing the main results in this work. Etomoxir decreases respiration while
increasing glycolytic activity. In addition, it causes oxidative stress (ROS over-production, GSH depletion)
which, together with AMPK activation, may explain the potentiation of ATO-provoked apoptosis. Etomoxir may
also cooperate in some cell models with glycolytic inhibitors (2-DG, lonidamine) to cause apoptosis. This
response is further enhanced by co-incubation with ATO, due to the capacity of this agent to attenuate the 2-
DG/etomoxir-provoked Akt and ERK activation.
doi:10.1371/journal.pone.0115250.g009
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kinase activation, as indicated by immunoblot assays and corroborated using
kinase pharmacologic inhibitors.
A scheme summarizing the main observations in this work is presented in
Fig. 9. Etomoxir causes cyto-reduction (cell cycle disruption, apoptosis induc-
tion), and what is more important potentiates the lethality of ATO, and with
lower efficacy of other conventional anti-tumour drugs in AML cells. The
sensitizing action of etomoxir is not adequately explained by energy depletion, but
may be in part explained by the capacity to generate moderate oxidative stress, as
evidenced by ROS production and GSH depletion, and to activate the LKB-1/
AMPK pro-apoptotic pathway. Moreover, higher apoptotic and sensitizing
responses may still be obtained by simultaneously targeting fatty acid and
glycolytic metabolism, although this response depends on the used cell type, and
the biochemical mechanisms accounting for this enhanced apoptotic response
remain to be elucidated. While this is an in vitro pre-clinical assay, we believe that
this information might be useful to design new therapeutic approaches based on
the use of energy pathway inhibitors.
Supporting Information
S1 Figure. AMP, ADP and ATP, as determined by HPLC. The figure shows
representative chromatograms identifying adenine nucleotide peaks in (A)
untreated HL60 cells (Cont), (B) cells incubated for 6 h with 100 mM etomoxir
plus 5 mM 2-DG, and (C) cells incubated for 2 h with 1 mM oligomycin plus
30 mM 2-DG.
doi:10.1371/journal.pone.0115250.s001 (TIF)
S2 Figure. Apoptosis induction, as determined by changes in nuclear
morphology. (A) Examples of chromatin distribution in untreated (Cont) and
etomoxir plus ATO-treated HL60 cells. Arrows indicate cells with condensed/
fragmented chromatin, and partial chromatin loss, characteristic of late apoptosis.
(B–F) Frequency of apoptosis in HL60 cell cultures treated with: (B) the indicated
concentrations of etomoxir and ATO, alone and in combination, and with or
without z-VAD-fmk; (C) the indicated concentrations of etomoxir and 2-DG,
alone and in combination; (D) ATO plus etomoxir plus 2-DG, in relation to ATO
plus etomoxir or ATO plus 2-DG; (E) etomoxir plus ATO or cisplatin, in the
absence (2) or the presence (+) of the AMPK inhibitor compound C (CC); (F)
etomoxir plus 2-DG, in the absence (2) or the presence of the MEK/ERK
inhibitor U0126 or the Akt inhibitor AktiV. All treatments lasted for 24 h. ATO
was always used at 2 mM. The results represent the mean¡ S.D. of at least three
determinations. Symbols mean: (*) significant differences between the indicated
pairs of values, and (#) significant differences between the combined treatment
and the sum of values in the corresponding single treatments. For more detailed
explanations, see legends of Figures 1 and 6 in the main text.
doi:10.1371/journal.pone.0115250.s002 (TIF)
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S3 Figure. Changes in total intracellular ATP levels in HL60 cells. The bar
charts show the changes in ATP, as determined by bioluminescence assays, upon
treatment for 4 h with: (A) the indicated concentrations of etomoxir; and (B) the
indicated concentrations of etomoxir, 2-DG, and 2 mM ATO, alone and in
combination. The results are expressed in relation to the control (approximate
ATP content, 20 nmol/106 cells). The results represent the mean¡ S.D. of at least
four determinations. Symbols indicate significant differences in relation to the
control (A), or between the indicated pairs of values (B) (n.s., non-significant).
For other conditions, see legend of Figure 1 in the main text.
doi:10.1371/journal.pone.0115250.s003 (TIF)
S4 Figure. Effect of orlistat and ATO on cell viability, apoptosis and cycle phase
distribution in HL60 cells. Cell cultures were incubated for 24 h with the
indicated concentrations of orlistat (Orl) and 2 mM ATO, alone and in
combination. (A) Changes in the number of viable cells, as evidenced by MTT
assay. Absorption values are indicated in relation to untreated (Cont) cultures. (B)
Frequency of apoptotic cells, as determined by flow cytometry. (C) Frequency of
cells at the different phases of the growth cycle, namely G1, S and G2/M, and with
sub-G1 DNA content (apoptotic). Examples of flow cytometry histograms are
presented in (D). The results in panels A–C represent the mean ¡ S.D. of four
determinations. Symbols mean: (*) significant differences between the indicated
pairs of values, and (#) significant differences between the combined treatment
and the sum of values in the corresponding single treatments (n.s., non-
significant). For more detailed explanations see legend of Figure 1 in the main
text.
doi:10.1371/journal.pone.0115250.s004 (TIF)
S1 Table. Effects of 2-DG, etomoxir and ATO on adenine nucleotide pool
distribution in HL60 cells. The table shows the changes in ATP, ADP, AMP pool
distribution in untreated cells (Cont), and cells exposed for 2 and/or 6 h to 1 mM
oligomycin plus 30 mM 2-DG (positive control), 2-DG (mM), etomoxir (mM)
and ATO (mM), alone or in combination. n, number of determinations. Energy
charge is defined as: ([ATP]+0.5[ADP])/[ATP+ADP+AMP] (see Atkinson DE
(1968) Biochemistry 7: 4030–4034).
doi:10.1371/journal.pone.0115250.s005 (TIF)
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